Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study

Introduction: Persisting cancer related fatigue (CRF) has impact on health quality of life (HRQoL) and social re-integration patients with Hodgkin lymphoma (HL). The GHSG HD18 trial established treatment PET-2 guided de-escalation for advanced-stage HL as new standard. Here, we investigate the in long-term HRQoL domains time-to-recovery from (TTR-F). Methods: Mean scores (FA) EORTC QLQ-C30 questionnaire are reported descriptively baseline, interim, end-of-treatment, yearly follow-up. TTR-F was defined time end chemotherapy until first occurrence FA <30 or last (censored). analyzed compared using time-to-event methods including cumulative incidence cox proportional hazard models, recommended by SISAQoL consortium. Effect disease, patient characteristics 2y multiple regression. Results: 2101 aged 18–60 years were recruited HD18, whom 156 found ineligible before after randomization. negative Patients randomized between 8x eBEACOPP (arm C, n = 288) 4x D; 285), 6x C6; 216) (D4; 216). questionnaires at baseline available 83.9% all patients. Overall, age significantly associated TTR-F, whereas sex not. differed arms negative, but not positive Particularly, reduction 8 to 4 cycles led a shorter (HR 1.41, p 0.008). Reducing cycle number 6 1.21, 0.2) 1.22, 0.18) speeded accordingly statistically significant. For PET-positive slower observed addition Rituximab 0.7, 0.0163). In PET-2-negative patients, median 19 months (CI95: 13–28) arm 13 10–20) C6, 12 8–15) D 10 8–13) D4. main determinants domains. research funded by: Deutsche Krebshilfe, Swiss State Secretariat Education Research, Roche Pharma AG. Keywords: Chemotherapy, lymphoma, Late Effects Lymphoma Survivors No conflicts interests pertinent abstract.